Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: February 15th, 2010 - February 15th, 2011

Target Audience
This activity was developed for pharmacists and other healthcare professionals practicing in a managed care environment.

Learning Objectives
At the completion of this activity participants should be able to:

  • Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving breast cancer treatment that providers are using as the basis for their treatment decisions
  • Offer payers a multistakeholder commentary on this information, to identify the impact on different stakeholders of these changes to treatment
  • Illuminate the different perspectives and incentives of the various stakeholders involved in breast cancer treatment decisions—patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
  • Align incentives with providers, and transform payer drug management policies into patient-centered, value-based models


Estimated time to complete activity: 1 hour

Pharmacists Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hours (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-011-H01-P.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.


Faculty Disclosures
James Kenney, RPh, MBA, has nothing to disclose.

*Content will include non-FDA-approved uses.

The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Payer Perspective ASH 2011 Update: Multiple Myeloma Treatment Trends and Strategies for Value-Based Care
Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA
Supplements published on March 5, 2012
The Evolving Role of Outcomes and End Points in Evaluating Therapy for Hematologic Malignancies: Value-Driven Benefit Design and Utilization Management Strategies
Gary C. Yee, PharmD, FCCP, BCOP, James T. Kenney Jr, RPh, MBA, Michael Mauro, MD
Supplements published on July 15, 2011
ASH 2010 Update on Multiple Myeloma: Treatment Trends and Strategies for Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on March 4, 2011
ASH 2010 Update on Non-Hodgkin Lymphoma: Alignment of the Current Treatment Landscape and Value-Based Care
John Fox, MD, James T. Kenney Jr, RPh, MBA
Supplements published on February 28, 2011
Last modified: March 24, 2014